95-22789. Findings of Scientific Misconduct

[Federal Register Volume 60, Number 178 (Thursday, September 14, 1995)]
[Notices]
[Page 47748]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-22789]



=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has made final findings of scientific misconduct in the following 
case:
    Catherine Kerr, St. Mary's Hospital: The Office of Research 
Integrity (ORI) conducted an investigation into possible scientific 
misconduct on the part of Ms. Catherine Kerr while she was a data 
coordinator at St. Mary's Hospital, Montreal, Quebec. ORI concluded 
that Ms. Kerr committed scientific misconduct by falsifying and 
fabricating the dates of tests or examinations required prior to study 
entry for one woman entered on the Breast Cancer Prevention Trial 
(BCPT). She also fabricated laboratory results and falsified dates of 
laboratory tests used to follow the progress of another woman entered 
on the trial. The BCPT is coordinated by the National Surgical Adjuvant 
Breast and Bowel Project (NSABP) and supported by the National Cancer 
Institute and the National Heart, Lung, and Blood Institute. Because 
the BCPT is still in progress, no conclusions or results have been 
published and no clinical recommendations have been based on the 
results of the study.
    Ms. Kerr originally appealed but later withdrew her request for a 
hearing on the ORI findings and administrative actions, which require 
that, for a period of three years, any institution that proposes Ms. 
Kerr's participation in PHS-supported research must submit a 
supervisory plan designed to ensure the scientific integrity of her 
contribution. Ms. Kerr is also prohibited from serving in any advisory 
capacity to PHS for a period of three years.

FOR FURTHER INFORMATION CONTACT: Director, Division of Research 
Investigations, Office of Research Integrity, 5515 Security Lane, Suite 
700, Rockville, MD 20852.
Lyle W. Bivens,
Director, Office of Research Integrity.
[FR Doc. 95-22789 Filed 9-13-95; 8:45 am]
BILLING CODE 4160-17-P